Prognostic impact of molecular markers in a series of 220 primary glioblastomas

Cancer

Volumn 106, Issue 10, 2006, Pages 2218-2223

  Houillier, Caroline ^a,b,c   Lejeune, Julie ^a,b,c   Benouaich Amiel, Alexandra ^a,b,c   Laigle Donadey, Florence ^a,b,c   Criniere, Emmanuelle ^a,b,c   Mokhtari, Karima ^c   Thillet, Joelle ^a,b,c   Delattre, Jean Yves ^a,b,c   Hoang Xuan, Khe ^a,b,c   Sanson, Marc ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

EGFR; Glioblastoma; Markers; MDM2; Prognosis

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE 4; MOLECULAR MARKER; PROTEIN MDM2; PROTEIN P16INK4A; PROTEIN P53;

ADULT; AGE; AGED; ARF GENE; ARTICLE; CARCINOGENESIS; CDK4 GENE; CDKN2A GENE; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 9P; DISEASE COURSE; EGFR GENE; FEMALE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC MARKER; GENETIC SCREENING; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INK4A GENE; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; BASE SEQUENCE; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; GENETIC MARKERS; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MDM2; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 33646379132     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21819     Document Type: Article

References (41)

1. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
2. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22:3133-3138.
3. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64:6892-6899.
4. Batchelor TT, Betensky RA, Espositi JM, et al. Age-dependant prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10:228-233.
5. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol. 2002;61:321-328.
6. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res. 2000;12:107-112.
7. Nieder C, Petersen S, Petersen C, Thames HD. The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev. 2000;26:67-73
8. Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognosis factors in the three Radiation Therapy Oncology group malignant gliomas trials. J Natl Cancer Inst. 1993;85:704-710.
9. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol. 2001;60:863-871.
10. Mokhtari K, Paris S, Aguirre-Cruz L, et al. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol. 2005;31:62-69.
11. Berggren P, Kumar R, Sakano S, et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res. 2003;9:235-242.
12. Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll B. Distribution of epidermal growth factor receptor gene amplification in brain tumors and correlation to prognosis. J Neurol. 1995;242:683-688.
13. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
14. Huhn SL, Mohapatra G, Bollen A, Lamborn K, Prados MD, Feuerstein BG. Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridisation: correlation with radiation treatment outcome. Clin Cancer Res. 1999;5:1435-1443.
15. Leenstra S, Oskam NT, Bijleveld EH, Bosch DA, Troost D, Hulsebos TJM. Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer. 1998;79:159-165.
16. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6:217-223.
17. Von Deimling A, Fimmers R, Schmidt MC, et al. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol. 2000;59:544-558.
18. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993-1000.
19. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001-5014.
20. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res. 1994;54:4299-4303.
21. Ichimura K, Schmidt EE, Goike HM, Collins W. Human glioblastomas with no alterations of the CDKN2A (P16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene. 1996;13:1065-1072.
22. Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP, Bamberg M. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol. 2000;49:197-203.
23. Rainov NG, Dobberstein KU, Bahn H, et al. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol. 1997;35:13-28.
24. Stark AM, Hugo HH, Witzel P, Mihajlovic Z, Mehdorn HM. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Zentralbl Neurochir. 2003;64:30-36.
25. Newcomb EW, Cohen H, Lee SR, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl2 genes. Brain Pathol. 1998;8:655-667.
26. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex association between age, P53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001;61:1122-1128.
27. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246-1156.
28. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63:6962-6970.
29. Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys. 1996;34:809-815.
30. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials. J Natl Cancer Inst Monogr. 1994;16:35-42.
31. Harrison JD, Fielding JW. Prognostic factors for gastric cancer influencing clinical practice. World J Surg. 1995;19:496-500.
32. Hodgson DC, Fuchs CS, Ayanian JZ. Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst. 2001;93:501-515.
33. Pelloski CE, Mahajan A, Maor M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res. 2005;11:3326-3334.
34. Ino Y, Zlatescu MC, Saski H, et al. Long survival and therapeutic response in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg. 2000;92:983-990.
35. Birner P, Piribauer M, Fischer I, et al. Prognostic relevance of p53 protein expression in glioblastoma. Oncol Rep. 2002;9:703-707.
36. Kirla R, Salminen E, Huhtala S, et al. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and pRb, and Ki-67 labelling in high grade astrocytomas treated by radiotherapy. J Neurooncol. 2000;46:71-80.
37. Weber RG, Sommer C, Albert FK, Kiessling M, Cremer T. Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridisation. Lab Invest. 1996;74:108-119.
38. Felsberg J, Erkwoh A, Sabel MC, et al. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q states with survival. Brain Pathol. 2004;14:121-130.
39. Hoang-Xuan K, He J, Huguet S, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology. 2001;57:1278-1281.
40. Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendrogliomas mimics. Front Biosci. 2003;8:a1-9.
41. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2005;102:5814-5819.